Cargando…
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients
BACKGROUND: Neuroblastoma is characterized by substantial clinical heterogeneity. Despite intensive treatment, the survival rates of high-risk neuroblastoma patients are still disappointingly low. Somatic chromosomal copy number aberrations have been shown to be associated with patient outcome, part...
Autores principales: | Depuydt, Pauline, Boeva, Valentina, Hocking, Toby D, Cannoodt, Robrecht, Ambros, Inge M, Ambros, Peter F, Asgharzadeh, Shahab, Attiyeh, Edward F, Combaret, Valérie, Defferrari, Raffaella, Fischer, Matthias, Hero, Barbara, Hogarty, Michael D, Irwin, Meredith S, Koster, Jan, Kreissman, Susan, Ladenstein, Ruth, Lapouble, Eve, Laureys, Geneviève, London, Wendy B, Mazzocco, Katia, Nakagawara, Akira, Noguera, Rosa, Ohira, Miki, Park, Julie R, Pötschger, Ulrike, Theissen, Jessica, Tonini, Gian Paolo, Valteau-Couanet, Dominique, Varesio, Luigi, Versteeg, Rogier, Speleman, Frank, Maris, John M, Schleiermacher, Gudrun, De Preter, Katleen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186524/ https://www.ncbi.nlm.nih.gov/pubmed/29514301 http://dx.doi.org/10.1093/jnci/djy022 |
Ejemplares similares
-
Meta-mining of copy number profiles of high-risk neuroblastoma tumors
por: Depuydt, Pauline, et al.
Publicado: (2018) -
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018) -
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
por: Ambros, Inge M., et al.
Publicado: (2020) -
Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017) -
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)